Generic versions of Janssen's Invega atypical antipsychotic are now available from Allergan and Mylan.
Generic versions of Janssen’s Invega atypical antipsychotic are now available from Allergan and Mylan.
These generic paliperidone extended-release tablets are offered in 1.5 mg, 3 mg, 6 mg, and 9 mg dosage strengths.
The drug is indicated to treat schizophrenia in adults and adolescents ages 12 to 17 years, in addition to schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants in adults.
"This launch reinforces Allergan's commitment to developing, manufacturing, and bringing to market high-quality, affordable versions of challenging products like Invega, benefiting patients and reducing health care costs," stated Robert Stewart, Allergan's executive vice president and president of generics and global operations.
Paliperidone is not approved to treat patients with dementia-related psychosis. Of note, elderly patients with this condition who receive antipsychotic drugs have an increased risk of death.
The drug is contraindicated in patients with known hypersensitivity to paliperidone, risperidone, or any other components in the formulation.